Compare Kinross Gold Corporation (KGC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinross Gold Corporation vs BIO-TECHNE Corp — how do they compare? Kinross Gold Corporation trades at $23.36 (market cap $26.63B), while BIO-TECHNE Corp trades at $71.72 (market cap $11.16B). The key difference: Kinross Gold Corporation is far larger — about 2.4× BIO-TECHNE Corp's market cap, and Kinross Gold Corporation pays the higher dividend (0.64%). Which is the better fit depends on your goals.
| KGC | TECH | |
|---|---|---|
Market Cap | $26.63B | $11.16B |
Sector | Basic Materials | Health |
52-Week High | $38.06 | $72.12 |
52-Week Low | $15.42 | $43.31 |
Enterprise Value | $25.18B | $11.24B |
Dividend Yield | 0.64% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinross Gold (KGC) trades at $22.65, up 0.35% with strong fundamentals including 35.99% net margin and 35.15% ROE. The stock shows bearish technical signals despite consistent earnings beats and analyst consensus of $37.20 price target. Recent cash flow growth from $259M in 2024 to $1.13B in 2025 supports dividend payments and exploration projects.
KGC presents value opportunity with P/E of 9.6x below industry averages, though technical weakness and gold price volatility pose risks. Production growth to 2.3M+ ounces by 2028 and net cash position provide upside catalysts if gold prices stabilize.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
